Skip to main content
Top
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

HP1γ expression is elevated in prostate cancer and is superior to Gleason score as a predictor of biochemical recurrence after radical prostatectomy

Authors: Jon Slezak, Matthew Truong, Wei Huang, David Jarrard

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

Aberrant chromatin structure in cancer cells results from altered proteins involved in its packaging. Heterochromatin protein 1 gamma (HP1γ) is a non-histone heterochromatic protein that functions to maintain chromatin stability and is important in embryonic development. Given an interest in the role developmental genes play in cancer, we investigated HP1γ expression in prostate cancer (PCa) and its prognostic associations.

Methods

Tissue microarrays consisting of benign (N = 96), localized cancer (N = 146), metastatic PCa (N = 44), and HGPIN (N = 50) were immunoflourescently stained for HP1γ and Ki-67. Using a novel, automated quantitative imaging system, VECTRA™, epithelial staining in both the nucleus and cytoplasm was quantified and compared against clinicopathologic variables.

Results

HP1γ is significantly elevated in HGPIN (80%), localized PCa (76%), and metastatic PCa (98%) compared to benign tissues from both the nuclear and cytoplasmic compartments (P < 0.0001). Increased nuclear and total HP1γ expression was associated with Gleason score (P = 0.02 and P = 0.04 respectively). Given known binding to the C-terminus of Ki-67, a co-expression analysis was performed that revealed a correlation between nuclear and cytoplasmic HP1γ and Ki-67 (Pearson Coefficient 0.321 and 0.562 respectively, P < 0.0001). Cox survival analysis demonstrated that cytoplasmic HP1γ expression was an independent prognostic marker and out-performed pathological Gleason score for predicting PSA-recurrence after radical prostatectomy.

Conclusions

In this first detailed analysis of HP1γ expression in cancer, VECTRA™ demonstrates compartmentalized and total HP1γ protein expression is increased in PCa and that expression correlates with clinical outcomes better than Gleason score. Given the critical role HP1γ plays in chromatin organization and gene expression, it represents a novel prognostic and therapeutic target.
Appendix
Available only for authorised users
Literature
1.
go back to reference Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 2012, 62 (1): 10-29. 10.3322/caac.20138.CrossRefPubMed Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 2012, 62 (1): 10-29. 10.3322/caac.20138.CrossRefPubMed
2.
go back to reference Schaeffer EM, Marchionni L, Huang Z, Simons B, Blackman A, Yu W, Parmigiani G, Berman DM: Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer. Oncogene. 2008, 27 (57): 7180-7191. 10.1038/onc.2008.327.CrossRefPubMedPubMedCentral Schaeffer EM, Marchionni L, Huang Z, Simons B, Blackman A, Yu W, Parmigiani G, Berman DM: Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer. Oncogene. 2008, 27 (57): 7180-7191. 10.1038/onc.2008.327.CrossRefPubMedPubMedCentral
4.
go back to reference Shapiro E, Huang H, Ruoff R, Lee P, Tanese N, Logan SK: The heterochromatin protein 1 family is regulated in prostate development and cancer. J Urol. 2008, 179 (6): 2435-2439. 10.1016/j.juro.2008.01.091.CrossRefPubMed Shapiro E, Huang H, Ruoff R, Lee P, Tanese N, Logan SK: The heterochromatin protein 1 family is regulated in prostate development and cancer. J Urol. 2008, 179 (6): 2435-2439. 10.1016/j.juro.2008.01.091.CrossRefPubMed
5.
go back to reference Takanashi M, Oikawa K, Fujita K, Kudo M, Kinoshita M, Kuroda M: Heterochromatin protein 1gamma epigenetically regulates cell differentiation and exhibits potential as a therapeutic target for various types of cancers. Am J Pathol. 2009, 174 (1): 309-316. 10.2353/ajpath.2009.080148.CrossRefPubMedPubMedCentral Takanashi M, Oikawa K, Fujita K, Kudo M, Kinoshita M, Kuroda M: Heterochromatin protein 1gamma epigenetically regulates cell differentiation and exhibits potential as a therapeutic target for various types of cancers. Am J Pathol. 2009, 174 (1): 309-316. 10.2353/ajpath.2009.080148.CrossRefPubMedPubMedCentral
6.
go back to reference Caillier M, Thénot S, Tribollet V, Birot AM, Samarut J, Mey A: Role of the epigenetic regulator HP1γ in the control of embryonic stem cell properties. PLoS One. 2010, 5 (11): e15507-10.1371/journal.pone.0015507.CrossRefPubMedPubMedCentral Caillier M, Thénot S, Tribollet V, Birot AM, Samarut J, Mey A: Role of the epigenetic regulator HP1γ in the control of embryonic stem cell properties. PLoS One. 2010, 5 (11): e15507-10.1371/journal.pone.0015507.CrossRefPubMedPubMedCentral
8.
go back to reference Canudas S, Houghtaling BR, Bhanot M, Sasa G, Savage SA, Bertuch AA, Smith S: A role for heterochromatin protein 1γ at human telomeres. Genes Dev. 2011, 25 (17): 1807-1819. 10.1101/gad.17325211.CrossRefPubMedPubMedCentral Canudas S, Houghtaling BR, Bhanot M, Sasa G, Savage SA, Bertuch AA, Smith S: A role for heterochromatin protein 1γ at human telomeres. Genes Dev. 2011, 25 (17): 1807-1819. 10.1101/gad.17325211.CrossRefPubMedPubMedCentral
9.
go back to reference Zhang R, Liu ST, Chen W, Bonner M, Pehrson J, Yen TJ, Adams PD: HP1 proteins are essential for a dynamic nuclear response that rescues the function of perturbed heterochromatin in primary human cells. Mol Cell Biol. 2007, 27 (3): 949-962. 10.1128/MCB.01639-06.CrossRefPubMed Zhang R, Liu ST, Chen W, Bonner M, Pehrson J, Yen TJ, Adams PD: HP1 proteins are essential for a dynamic nuclear response that rescues the function of perturbed heterochromatin in primary human cells. Mol Cell Biol. 2007, 27 (3): 949-962. 10.1128/MCB.01639-06.CrossRefPubMed
10.
go back to reference Luijsterburg MS, Dinant C, Lans H, Stap J, Wiernasz E, Lagerwerf S, Warmerdam DO, Lindh M, Brink MC, Dobrucki JW: Heterochromatin protein 1 is recruited to various types of DNA damage. J Cell Biol. 2009, 185 (4): 577-586. 10.1083/jcb.200810035.CrossRefPubMedPubMedCentral Luijsterburg MS, Dinant C, Lans H, Stap J, Wiernasz E, Lagerwerf S, Warmerdam DO, Lindh M, Brink MC, Dobrucki JW: Heterochromatin protein 1 is recruited to various types of DNA damage. J Cell Biol. 2009, 185 (4): 577-586. 10.1083/jcb.200810035.CrossRefPubMedPubMedCentral
11.
go back to reference Tanaka M, Chang P, Li Y, Li D, Overman M, Maru DM, Sethi S, Phillips J, Bland GL, Abbruzzese JL: Association of CHFR promoter methylation with disease recurrence in locally advanced colon cancer. Clin Cancer Res. 2011, 17 (13): 4531-4540. 10.1158/1078-0432.CCR-10-0763.CrossRefPubMed Tanaka M, Chang P, Li Y, Li D, Overman M, Maru DM, Sethi S, Phillips J, Bland GL, Abbruzzese JL: Association of CHFR promoter methylation with disease recurrence in locally advanced colon cancer. Clin Cancer Res. 2011, 17 (13): 4531-4540. 10.1158/1078-0432.CCR-10-0763.CrossRefPubMed
12.
go back to reference Kirschmann DA, Lininger RA, Gardner LM, Seftor EA, Odero VA, Ainsztein AM, Earnshaw WC, Wallrath LL, Hendrix MJ: Down-regulation of HP1Hsalpha expression is associated with the metastatic phenotype in breast cancer. Cancer Res. 2000, 60 (13): 3359-3363.PubMed Kirschmann DA, Lininger RA, Gardner LM, Seftor EA, Odero VA, Ainsztein AM, Earnshaw WC, Wallrath LL, Hendrix MJ: Down-regulation of HP1Hsalpha expression is associated with the metastatic phenotype in breast cancer. Cancer Res. 2000, 60 (13): 3359-3363.PubMed
13.
go back to reference Scholzen T, Endl E, Wohlenberg C, van der Sar S, Cowell IG, Gerdes J, Singh PB: The Ki-67 protein interacts with members of the heterochromatin protein 1 (HP1) family: a potential role in the regulation of higher-order chromatin structure. J Pathol. 2002, 196 (2): 135-144. 10.1002/path.1016.CrossRefPubMed Scholzen T, Endl E, Wohlenberg C, van der Sar S, Cowell IG, Gerdes J, Singh PB: The Ki-67 protein interacts with members of the heterochromatin protein 1 (HP1) family: a potential role in the regulation of higher-order chromatin structure. J Pathol. 2002, 196 (2): 135-144. 10.1002/path.1016.CrossRefPubMed
14.
go back to reference Huang W, Hennrick K, Sally Drew BS M: A colorful future of quantitative pathology: validation of Vectra technology using chromogenic multiplexed immunohistochemistry and prostate tissue microarrays. Hum Pathol. 2012, in press Huang W, Hennrick K, Sally Drew BS M: A colorful future of quantitative pathology: validation of Vectra technology using chromogenic multiplexed immunohistochemistry and prostate tissue microarrays. Hum Pathol. 2012, in press
15.
go back to reference Ogawa H, Ishiguro K, Gaubatz S, Livingston DM, Nakatani Y: A complex with chromatin modifiers that occupies E2F- and Myc-responsive genes in G0 cells. Science. 2002, 296 (5570): 1132-1136. 10.1126/science.1069861.CrossRefPubMed Ogawa H, Ishiguro K, Gaubatz S, Livingston DM, Nakatani Y: A complex with chromatin modifiers that occupies E2F- and Myc-responsive genes in G0 cells. Science. 2002, 296 (5570): 1132-1136. 10.1126/science.1069861.CrossRefPubMed
16.
go back to reference Gerdes J, Schwab U, Lemke H, Stein H: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983, 31 (1): 13-20. 10.1002/ijc.2910310104.CrossRefPubMed Gerdes J, Schwab U, Lemke H, Stein H: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983, 31 (1): 13-20. 10.1002/ijc.2910310104.CrossRefPubMed
17.
go back to reference Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984, 133 (4): 1710-1715.PubMed Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984, 133 (4): 1710-1715.PubMed
18.
go back to reference Chun FK, Briganti A, Graefen M, Porter C, Montorsi F, Haese A, Scattoni V, Borden L, Steuber T, Salonia A: Development and external validation of an extended repeat biopsy nomogram. J Urol. 2007, 177 (2): 510-515. 10.1016/j.juro.2006.09.025.CrossRefPubMed Chun FK, Briganti A, Graefen M, Porter C, Montorsi F, Haese A, Scattoni V, Borden L, Steuber T, Salonia A: Development and external validation of an extended repeat biopsy nomogram. J Urol. 2007, 177 (2): 510-515. 10.1016/j.juro.2006.09.025.CrossRefPubMed
19.
go back to reference Veltri RW, Isharwal S, Miller MC, Epstein JI, Mangold LA, Humphreys E, Partin AW: Long-term assessment of prostate cancer progression free survival: evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis. Prostate. 2008, 68 (16): 1806-1815. 10.1002/pros.20848.CrossRefPubMedPubMedCentral Veltri RW, Isharwal S, Miller MC, Epstein JI, Mangold LA, Humphreys E, Partin AW: Long-term assessment of prostate cancer progression free survival: evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis. Prostate. 2008, 68 (16): 1806-1815. 10.1002/pros.20848.CrossRefPubMedPubMedCentral
20.
go back to reference Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, Mesher D, Speights VO, Stankiewicz E, Foster CS: Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011, 12 (3): 245-255. 10.1016/S1470-2045(10)70295-3.CrossRefPubMedPubMedCentral Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, Mesher D, Speights VO, Stankiewicz E, Foster CS: Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011, 12 (3): 245-255. 10.1016/S1470-2045(10)70295-3.CrossRefPubMedPubMedCentral
21.
go back to reference Kamakaka RT: Heterochromatin: proteins in flux lead to stable repression. Curr Biol. 2003, 13 (8): R317-319. 10.1016/S0960-9822(03)00236-7.CrossRefPubMed Kamakaka RT: Heterochromatin: proteins in flux lead to stable repression. Curr Biol. 2003, 13 (8): R317-319. 10.1016/S0960-9822(03)00236-7.CrossRefPubMed
22.
go back to reference Lomberk G, Bensi D, Fernandez-Zapico ME, Urrutia R: Evidence for the existence of an HP1-mediated subcode within the histone code. Nat Cell Biol. 2006, 8 (4): 407-415. 10.1038/ncb1383.CrossRefPubMed Lomberk G, Bensi D, Fernandez-Zapico ME, Urrutia R: Evidence for the existence of an HP1-mediated subcode within the histone code. Nat Cell Biol. 2006, 8 (4): 407-415. 10.1038/ncb1383.CrossRefPubMed
23.
go back to reference Minc E, Courvalin JC, Buendia B: HP1gamma associates with euchromatin and heterochromatin in mammalian nuclei and chromosomes. Cytogenet Cell Genet. 2000, 90 (3–4): 279-284.CrossRefPubMed Minc E, Courvalin JC, Buendia B: HP1gamma associates with euchromatin and heterochromatin in mammalian nuclei and chromosomes. Cytogenet Cell Genet. 2000, 90 (3–4): 279-284.CrossRefPubMed
24.
go back to reference Bettencourt MC, Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Moul JW: Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol. 1996, 156 (3): 1064-1068. 10.1016/S0022-5347(01)65703-3.CrossRefPubMed Bettencourt MC, Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Moul JW: Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol. 1996, 156 (3): 1064-1068. 10.1016/S0022-5347(01)65703-3.CrossRefPubMed
Metadata
Title
HP1γ expression is elevated in prostate cancer and is superior to Gleason score as a predictor of biochemical recurrence after radical prostatectomy
Authors
Jon Slezak
Matthew Truong
Wei Huang
David Jarrard
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-148

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine